留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌术后复发的外科治疗研究现状及进展

林鹏 蔡敏清 房俊伟 刘建勇 江艺

林鹏, 蔡敏清, 房俊伟, 等. 肝癌术后复发的外科治疗研究现状及进展[J]. 器官移植, 2022, 13(1): 111-119. doi: 10.3969/j.issn.1674-7445.2022.01.017
引用本文: 林鹏, 蔡敏清, 房俊伟, 等. 肝癌术后复发的外科治疗研究现状及进展[J]. 器官移植, 2022, 13(1): 111-119. doi: 10.3969/j.issn.1674-7445.2022.01.017
Lin Peng, Cai Minqing, Fang Junwei, et al. Research status and progress on surgical treatment of postoperative recurrence of hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 111-119. doi: 10.3969/j.issn.1674-7445.2022.01.017
Citation: Lin Peng, Cai Minqing, Fang Junwei, et al. Research status and progress on surgical treatment of postoperative recurrence of hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 111-119. doi: 10.3969/j.issn.1674-7445.2022.01.017

肝癌术后复发的外科治疗研究现状及进展

doi: 10.3969/j.issn.1674-7445.2022.01.017
基金项目: 

福建省自然科学基金引导性项目 2020Y0078

详细信息
    作者简介:

    林鹏,男,1995年生,本科,研究方向为肝移植,Email:linpeng0507@163.com

    通讯作者:

    江艺,Email:jiangyi8183@163.com

  • 中图分类号: R617, R575

Research status and progress on surgical treatment of postoperative recurrence of hepatocellular carcinoma

More Information
  • 摘要: 肝细胞癌(肝癌)是全球范围内最常见恶性肿瘤之一,目前肝切除术是其最常用的治疗方法之一,但其术后高复发率严重影响患者的长期生存。因此,选择合适的治疗方案治疗肝癌复发以期改善患者长期生存迫在眉睫。外科治疗是复发性肝癌的有效治疗手段,包括再次肝切除、补救性肝移植和射频消融。目前,肝癌术后复发提倡个体化治疗,治疗选择应基于首次肝切除时肿瘤情况、复发肿瘤特征、患者基本情况及复发时间等,为患者制定合理治疗方案。本文对上述外科治疗方案进行回顾和比较,以分析肝癌术后复发较为合理的外科治疗方案,旨在为延长患者生存时间提供参考。

     

  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.

    ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.
    [3] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020, 40(2): 121-138. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.01.

    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of primary hepatic carcinom (2019 edition)[J]. Chin J Pract Surg, 2020, 40(2): 121-138. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.01.
    [4] 国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2021, 41(1): 20-30. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.03.

    Expert Group of the State Key Project on Infectious Diseases on"Novel Strategies of Comprehensive and Individualizd Surgical Treatment of Viral Hepatitis-related Liver Cancer" from the Ministry of Science and Technology of China. Chinese expert consensus on the preventation and management of recurrent hepatocellular carcinoma after hepatic resection(2020 edition)[J]. Chin J Pract Surg, 2021, 41(1): 20-30. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.03.
    [5] XING H, SUN LY, YAN WT, et al. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: a multicenter propensity score matching analysis[J]. Surgery, 2021, 169(4): 911-920. DOI: 10.1016/j.surg.2019.11.005.
    [6] HU Z, ZHOU J, LI Z, et al. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus[J]. Surgery, 2015, 157(2): 239-248. DOI: 10.1016/j.surg.2014.09.018.
    [7] FANG JZ, XIANG L, HU YK, et al. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: salvage liver transplantation or rehepatectomy?[J]. Clin Transplant, 2020, 34(5): e13831. DOI: 10.1111/ctr.13831.
    [8] GUO Y, TAN EK, SYN NL, et al. Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: a propensity score-adjusted and -matched comparison analysis[J]. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 305-312. DOI: 10.14701/ahbps.2019.23.4.305.
    [9] YANG D, ZHUANG B, WANG Y, et al. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated Meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 402. DOI: 10.1186/s12876-020-01544-0.
    [10] XIA Y, LI J, LIU G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial[J]. JAMA Oncol, 2020, 6(2): 255-263. DOI: 10.1001/jamaoncol.2019.4477.
    [11] FENG Y, WU H, HUANG DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection[J]. Eur Radiol, 2020, 30(11): 6357-6368. DOI: 10.1007/s00330-020-06990-8.
    [12] 陈康, 刘新宇, 滕煜宪, 等. 再次肝切除与射频消融治疗复发性肝癌疗效对比研究[J]. 中国实用外科杂志, 2019, 39(10): 1060-1064. DOI: 10.19538/j.cjps.issn1005-2208.2019.10.16.

    CHEN K, LIU XY, TENG YX, et al. Rehepatectomy and radiofrequency ablation for patients with recurrent hepatocellular carcinoma[J]. Chin J Pract Surg, 2019, 39(10): 1060-1064. DOI: 10.19538/j.cjps.issn1005-2208.2019.10.16.
    [13] LIM C, SHINKAWA H, HASEGAWA K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: an intent-to-treat analysis[J]. Liver Transpl, 2017, 23(12): 1553-1563. DOI: 10.1002/lt.24952.
    [14] 杜苏明, 张小进, 江艺. 补救性肝移植和再次肝切除治疗肝癌术后复发的疗效对比[J]. 局解手术学杂志, 2016, 25(6): 409-412. DOI: 10.11659/jjssx.03E016097.

    DU SM, ZHANG XJ, JIANG Y, et al. Comparative effect of salvage liver transplantation and repeated hepatectomy for recurrent hepatocellular carcinoma[J]. J Reg Anat Oper Surg, 2016, 25(6): 409-412. DOI: 10.11659/jjssx.03E016097.
    [15] SUN WC, CHEN IS, LIANG HL, et al. Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection[J]. Oncotarget, 2017, 8(61): 104571-104581. DOI: 10.18632/oncotarget.21604.
    [16] YIN XL, HUA TQ, LIANG C, et al. Efficacy of re-resection versus radiofrequency ablation for recurrent Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma (HCC) after resection for primary HCC[J]. Transl Cancer Res, 2019, 8(4): 1035-1045. DOI: 10.21037/tcr.2019.06.11.
    [17] 刘嘉龙, 黄登, 曹利, 等. 腹腔镜肝切除术和射频消融术治疗复发性肝癌的前瞻性随机对照研究(中期随访分析)[J]. 第三军医大学学报, 2019, 41(5): 467-472. DOI: 10.16016/j.1000-5404.201811005.

    LIU JL, HUANG D, CAO L, et al. Laparoscopic hepatectomy versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma: a prospective randomized control study based on interim follow-up analysis[J]. J Third Mil Med Univ, 2019, 41(5): 467-472. DOI: 10.16016/j.1000-5404.201811005.
    [18] PENG Z, WEI M, CHEN S, et al. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study[J]. Eur Radiol, 2018, 28(8): 3522-3531. DOI: 10.1007/s00330-017-5166-4.
    [19] CHEN S, PENG Z, XIAO H, et al. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery[J]. Int J Hyperthermia, 2018, 34(7): 1029-1037. DOI: 10.1080/02656736.2017.1387941.
    [20] ZHANG X, LI C, WEN T, et al. Outcomes of salvage liver transplantation and re-resection/radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: a new surgical strategy based on recurrence pattern[J]. Dig Dis Sci, 2018, 63(2): 502-514. DOI: 10.1007/s10620-017-4861-y.
    [21] ZHANG X, LI C, WEN T, et al. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: salvage liver transplantation or re-resection/radiofrequency ablation? a retrospective cohort study[J]. Int J Surg, 2017, 46: 178-185. DOI: 10.1016/j.ijsu.2017.09.001.
    [22] SHAN Y, HUANG L, XIA Q. Salvage liver transplantation leads to poorer outcome in hepatocellular carcinoma compared with primary liver transplantation[J]. Sci Rep, 2017, 7: 44652. DOI: 10.1038/srep44652.
    [23] XIAO H, CHEN ZB, JIN HL, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy[J]. Am J Transl Res, 2019, 11(3): 1864-1875. http://www.ncbi.nlm.nih.gov/pubmed/30972210
    [24] YOH T, SEO S, TAURA K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival[J]. Ann Surg, 2021, 273(4): 792-799. DOI: 10.1097/SLA.0000000000003358.
    [25] YAGI R, MIDORIKAWA Y, MORIGUCHI M, et al. Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria[J]. Surgery, 2018, 163(6): 1250-1256. DOI: 10.1016/j.surg.2017.12.022.
    [26] ZOU Q, LI J, WU D, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Ann Surg Oncol, 2016, 23(8): 2618-2626. DOI: 10.1245/s10434-016-5136-0.
    [27] FANG Q, YANG R, CHEN D, et al. A novel nomogram to predict prolonged survival after hepatectomy in repeat recurrent hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 646638. DOI: 10.3389/fonc.2021.646638.
    [28] LIANG Y, LIN C, ZHANG B, et al. Perioperative outcomes comparing laparoscopic with open repeat liver resection for post-hepatectomy recurrent liver cancer: a systematic review and Meta-analysis[J]. Int J Surg, 2020, 79: 17-28. DOI: 10.1016/j.ijsu.2020.03.052.
    [29] ONOE T, YAMAGUCHI M, IREI T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma[J]. Surg Endosc, 2020, 34(10): 4574-4581. DOI: 10.1007/s00464-019-07246-3.
    [30] CAI W, LIU Z, XIAO Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a Meta-analysis[J]. Surg Endosc, 2019, 33(11): 3550-3557. DOI: 10.1007/s00464-019-06996-4.
    [31] DI SANDRO S, DANIELI M, FERLA F, et al. The current role of laparoscopic resection for HCC: a systematic review of past ten years[J]. Transl Gastroenterol Hepatol, 2018, 3: 68. DOI: 10.21037/tgh.2018.08.05.
    [32] OME Y, HASHIDA K, YOKOTA M, et al. The feasibility and efficacy of pure laparoscopic repeat hepatectomy[J]. Surg Endosc, 2018, 32(8): 3474-3479. DOI: 10.1007/s00464-018-6066-7.
    [33] LIU K, CHEN Y, WU X, et al. Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study[J]. Surg Endosc, 2017, 31(11): 4790-4798. DOI: 10.1007/s00464-017-5556-3.
    [34] 欧阳正晟, 唐朝晖, 吕丽娟, 等. 腹腔镜肝切除与开腹肝切除治疗原发性肝癌的临床比较[J]. 中国普通外科杂志, 2017, 26(1): 126-130. DOI: 10.3978/j.issn.1005-6947.2017.01.021.

    OUYANG ZS, TANG CH, LYU LJ, et al. Clinical comparison of laparoscopic and open hepatectomy in treatment of primary hepatic cancer[J]. Chin J Gen Surg, 2017, 26(1): 126-130. DOI: 10.3978/j.issn.1005-6947.2017.01.021.
    [35] MACHAIRAS N, PAPACONSTANTINOU D, STAMOPOULOS P, et al. The emerging role of laparoscopic liver resection in the treatment of recurrent hepatocellular carcinoma: a systematic review[J]. Anticancer Res, 2018, 38(5): 3181-3186. DOI: 10.21873/anticanres.12582.
    [36] ZHANG J, ZHOU ZG, HUANG ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma[J]. Chin J Cancer, 2016, 35: 25. DOI: 10.1186/s40880-016-0088-0.
    [37] CHEUNG TT, POON RT, DAI WC, et al. Pure laparoscopic versus open left lateral sectionectomy for hepatocellular carcinoma: a single-center experience[J]. World J Surg, 2016, 40(1): 198-205. DOI: 10.1007/s00268-015-3237-8.
    [38] MAJNO PE, SARASIN FP, MENTHA G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis[J]. Hepatology, 2000, 31(4): 899-906. DOI: 10.1053/he.2000.5763.
    [39] WANG P, PU Y, LI H, et al. Prognosis for recipients with hepatocellular carcinoma of salvage liver transplantation versus those of primary liver transplantation: a retrospective single-center study[J]. Springerplus, 2016, 5(1): 1809. DOI: 10.1186/s40064-016-3441-5.
    [40] GUO Y, TAN EK, KRISHNAMOORTHY TL, et al. Outcomes of salvage liver transplant for recurrent hepatocellular carcinoma: a comparison with primary liver transplant[J]. Ann Hepatobiliary Pancreat Surg, 2019, 23(1): 1-7. DOI: 10.14701/ahbps.2019.23.1.1.
    [41] HU Z, ZHOU J, XU X, et al. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection[J]. PLoS One, 2012, 7(5): e36587. DOI: 10.1371/journal.pone.0036587.
    [42] XIONG Q, GENG TT, HE L, et al. Harm and benefits of salvage transplantation for hepatocellular carcinoma: an updated Meta-analysis[J]. Transplant Proc, 2016, 48(10): 3336-3347. DOI: 10.1016/j.transproceed.2016.09.047.
    [43] 王翀, 徐敏, 李明阳, 等. 挽救性肝移植与原位肝移植对肝癌患者临床疗效的Meta分析[J]. 中华肝胆外科杂志, 2019, 25(1): 10-14. DOI: 10.3760/cma.j.issn.1007-8118.2019.01.003.

    WANG C, XU M, LI MY, et al. To compare salvage liver transplantation with othotopic liver transplantation for patients with hepatocellular carcinoma: a Meta-analysis[J]. Chin J Hepatobiliary Surg, 2019, 25(1): 10-14. DOI: 10.3760/cma.j.issn.1007-8118.2019.01.003.
    [44] 王洪良, 董建辉, 蓝柳根, 等. 补救性肝移植临床疗效的系统评价[J/CD]. 中华移植杂志(电子版), 2017, 11(3): 177-183. DOI: 10.3877/cma.j.issn.1674-3903.2017.03.011.

    WANG HL, DONG JH, LAN LG, et al. Clinical effect of salvage liver transplantation in the treatment of recurrent hepatocellular carcinoma after hepatectomy: a systematic review[J/CD]. Chin J Transplant (Electr Edit), 2017, 11(3): 177-183. DOI: 10.3877/cma.j.issn.1674-3903.2017.03.011.
    [45] BHANGUI P, ALLARD MA, VIBERT E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes?[J]. Ann Surg, 2016, 264(1): 155-163. DOI: 10.1097/SLA.0000000000001442.
    [46] LIN CC, ELSARAWY AM, LI WF, et al. Liver transplantation for high risk hepatocellular carcinoma after liver resection: a sequential or salvage approach?[J]. Ann Transplant, 2017, 22: 602-610. DOI: 10.12659/aot.905779.
    [47] FERRER-FÀBREGA J, FORNER A, LICCIONI A, et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection[J]. Hepatology, 2016, 63(3): 839-849. DOI: 10.1002/hep.28339.
    [48] YANG PC, HO CM, HU RH, et al. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma[J]. World J Hepatol, 2016, 8(31): 1309-1317. DOI: 10.4254/wjh.v8.i31.1309.
    [49] CHAN KM, WU TH, CHENG CH, et al. Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection[J]. Biomed J, 2019, 42(5): 335-342. DOI: 10.1016/j.bj.2019.04.001.
    [50] 高本见, 罗佳, 刘莹, 等. 挽救性肝移植与再次肝切除治疗术后复发性肝癌疗效对比的Meta分析[J]. 中国普通外科杂志, 2020, 29(1): 1-10. DOI: 10.7659/j.issn.1005-6947.2020.01.001.

    GAO BJ, LUO J, LIU Y, et al. Clinical efficacy of salvage liver transplantation versus repeat hepatectomy for recurrent hepatocellular carcinoma after hepatectomy: a Meta-analysis[J]. Chin J Gen Surg, 2020, 29(1): 1-10. DOI: 10.7659/j.issn.1005-6947.2020.01.001.
    [51] KOSTAKIS ID, MACHAIRAS N, PRODROMIDOU A, et al. Comparison between salvage liver transplantation and repeat liver resection for recurrent hepatocellular carcinoma: a systematic review and Meta-analysis[J]. Transplant Proc, 2019, 51(2): 433-436. DOI: 10.1016/j.transproceed.2019.01.072.
    [52] MA KW, CHOK KSH, SHE WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: a propensity score matched analysis[J]. Liver Transpl, 2018, 24(8): 1062-1069. DOI: 10.1002/lt.25033.
    [53] KIM JM, JOH JW, YI NJ, et al. Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection[J]. Ann Transl Med, 2020, 8(6): 288. DOI: 10.21037/atm.2020.02.170.
    [54] ABE T, TASHIRO H, TERAOKA Y, et al. Efficacy and feasibility of salvage living donor liver transplantation after initial liver resection in patients with hepatocellular carcinoma[J]. Dig Surg, 2016, 33(1): 8-14. DOI: 10.1159/000441397.
    [55] YAMASHITA Y, YOSHIDA Y, KURIHARA T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy versus salvage living donor liver transplantation[J]. Liver Transpl, 2015, 21(7): 961-968. DOI: 10.1002/lt.24111.
    [56] KIM SH, KIM KH, HA TY, et al. Salvage living donor liver transplantation for recurrent hepatocellular carcinoma after prior laparoscopic hepatectomy[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(5): 473-476. DOI: 10.1016/j.hbpd.2018.09.014.
    [57] ZHANG HM, SHI YX, SUN LY, et al. Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and Meta-analysis[J]. Chin Med J (Engl), 2019, 132(13): 1599-1609. DOI: 10.1097/CM9.0000000000000287.
    [58] LEE EC, KIM SH, SHIM JR, et al. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond Milan criteria[J]. Liver Transpl, 2018, 24(1): 35-43. DOI: 10.1002/lt.24868.
    [59] MA KW, WONG KHC, CHAN ACY, et al. Impact of small-for-size liver grafts on medium-term and long-term graft survival in living donor liver transplantation: a Meta-analysis[J]. World J Gastroenterol, 2019, 25(36): 5559-5568. DOI: 10.3748/wjg.v25.i36.5559.
    [60] HUANG Y, SONG J, ZHENG J, et al. Comparison of hepatic resection combined with intraoperative radiofrequency ablation, or hepatic resection alone, for hepatocellular carcinoma patients with multifocal tumors meeting the University of California San Francisco (UCSF) criteria: a propensity score-matched analysis[J]. Ann Surg Oncol, 2020, 27(7): 2334-2345. DOI: 10.1245/s10434-020-08231-0.
    [61] 邱华, 项灯, 万仁华, 等. 射频消融辅助肝切除治疗原发性肝癌的临床应用[J]. 中国现代医学杂志, 2018, 28(10): 115-118. DOI: 10.3969/j.issn.1005-8982.2018.10.021.

    QIU H, XIANG D, WAN RH, et al. Clinical application of radiofrequency ablation assisted hepatectomy to primary hepatocellural carcinoma[J]. Chin J Mod Med, 2018, 28(10): 115-118. DOI: 10.3969/j.issn.1005-8982.2018.10.021.
    [62] 史瑶平, 池嘉昌, 施东华, 等. 局部消融治疗术后单发复发肝细胞癌长期生存研究[J]. 中国实用外科杂志, 2020, 40(6): 710-714. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.19.

    SHI YP, CHI JC, SHI DH, et al. Long-term survival of local ablation for single recurrent hepatocellular carcinoma after liver resection[J]. Chin J Pract Surg, 2020, 40(6): 710-714. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.19.
    [63] LU LH, MEI J, KAN A, et al. Treatment optimization for recurrent hepatocellular carcinoma: repeat hepatic resection versus radiofrequency ablation[J]. Cancer Med, 2020, 9(9): 2997-3005. DOI: 10.1002/cam4.2951.
    [64] WANG P, LI H, SHI B, et al. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study[J]. Oncotarget, 2016, 7(23): 35071-35083. DOI: 10.18632/oncotarget.9040.
    [65] SAITO R, AMEMIYA H, HOSOMURA N, et al. Prognostic significance of treatment strategies for the recurrent hepatocellular carcinomas after radical resection[J]. In Vivo, 2020, 34(3): 1265-1270. DOI: 10.21873/invivo.11900.
    [66] JUNG SM, KIM JM, CHOI GS, et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma[J]. J Gastrointest Surg, 2019, 23(2): 304-311. DOI: 10.1007/s11605-018-3927-2.
    [67] XU XF, XING H, HAN J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J]. JAMA Surg, 2019, 154(3): 209-217. DOI: 10.1001/jamasurg.2018.4334.
    [68] SONG Q, REN W, FAN L, et al. Long-term outcomes oftransarterial chemoembolization combined with radiofrequency ablation versus transarterial chemoembolization alone for recurrent hepatocellular carcinoma after surgical resection[J]. Dig Dis Sci, 2020, 65(4): 1266-1275. DOI: 10.1007/s10620-019-05733-0.
    [69] PENG Z, CHEN S, WEI M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 287(2): 705-714. DOI: 10.1148/radiol.2018171541.
  • 加载中
图(1)
计量
  • 文章访问数:  167
  • HTML全文浏览量:  116
  • PDF下载量:  33
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-16
  • 网络出版日期:  2022-01-12
  • 刊出日期:  2022-01-15

目录

    /

    返回文章
    返回